|
|
WRF Venture Center Tenants
WRF Venture Center tenants are not necessarily part of the WRF investment
portfolio. Please see
Portfolio Companies for a list of those companies in which WRF has made an
investment.
 Targeted Growth, Inc.
Targeted Growth is commercializing technology that regulates the growth of plants. This will increase yields and decrease costs in agricultural applications.
Contact: Dr. George Todaro, Chief Executive Officer
Tel: (206) 336-5570
Fax: (206) 336-5573
Email: main@targetedgrowth.com
URL: www.targetedgrowth.com
|
SEMERON Corporation
Where big business capability meets entrepreneurial agility. We partner with you to deliver high-impact results fast.
Tel: (206) 686-1360
Email: info@semeron.com
URL: www.semeron.com
|
Avogadro Partners LLC
Avogadro is a Seattle, Washington based venture development and investment firm that focuses on building technology companies with a special focus on Small Technology: nano- and micro- technologies. We believe that significant companies are best built in close working partnerships with entrepreneurs.
Our approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates-of-return for both entrepreneurs and investors.
Contacts:
Jim Moore, Managing Partner
Tel: (206) 336-5576
Jim Stanton, Managing Partner
Tel: (206) 336-5598
URL: www.Avogadro.us
|
Revitalization Partners LLC
Revitalization Partners is an international specialty management services
firm that provides hands-on interim executive management and advisory
services to client companies. We specialize in under performing,
turnaround, bankruptcy and workout situations as well as repositioning
companies faced with changing market and funding situations.Contacts:
Al Davis, Principal
Tel: (206) 903-1855
Bill Lawrence, Principal
Tel: (206) 903-1855
URL:
www.RevitalizationPartners.com
|
|
Allez PhysiOnix Allez PhysiOnix, in
collaboration with Dr. Pierre D. Mourad, Research Associate Professor of the
Department of Neurological Surgery and Principal Physicist of the Applied
Physics Lab, both at the University of Washington, have developed a
methodology to non-invasively determine intracranial pressure (ICP), a
critical determinant of brain function. Head trauma is the major cause of
death in persons under the age of 45, typically due to increased ICP.
Intracranial pressure can also result from tumors, stroke, and other
neurological disorders. More than 1 million patents may need their ICP
monitored each year. Currently there is no non-invasive method for
determining the levels of ICP. It can only be measured through highly
invasive procedures requiring the participation of neurosurgeons. ICP
monitoring is only conducted for 100,000 patients per year. This limited
monitoring hinders the early diagnosis of many brain maladies, and reduces
the chance of successful treatment of these maladies. A simple non-invasive
method of monitoring ICP would allow early measurement both in and outside
of a hospital setting, and should improve the medical outcome for many
patients. In an initial project, the team developed an empirical method to
determine ICP non-invasively based on transcranial Doppler (TCD)
measurements of the brain and supporting physiological data. Currently the
device requires the services of a skilled neuro-sonographer to manipulate
the transducer. This project will help to evolve the technology to the point
that it can be more easily deployed, without special skills, in a
user-independent manner.
Contacts:
Boris Gelfenbeyn, Business Analyst/Clinical Coordinator
Tel: (206) 336-5566
|
|
AmKor Pharma AmKor Pharma is a biopharmaceutical company with a
clinical-stage focus on products that treat the body’s response to injury. AmKor’s lead product candidate is designed to treat ischemic stroke that
shows greater in vitro activity and more
safety than compounds previously tested in humans.
Contact:
Robert Littauer
Tel: (206) 336-5587
Email: rlittauer@amkorpharma.com
|
|
Arrowsmith Technologies
Arrowsmith Technologies Corporation is a seed-stage biotechnology
company whose founding technology is a method of using antibodies to
regulate the dosage of drugs. Its first application will be a novel
therapy for brain cancer.
Contact:
Tel: 206-291-7555
|
BECAUZ! is an adventure-based learning company that
specializes in high impact
training for teams and businesses.
Our
training is one of a kind. We completely immerse participants
in a series of simulations – a dynamic game that
engages their full potential and
creates immediate and remarkable results.
The BECAUZ! Game focuses on Teambuilding, Sales, Leadership and
Client Service, guaranteeing transformation in an
extraordinarily short period of time.
Contact:
Ian McKelvie
Tel: (206) 310-1525
|
|
TeachTown TeachTown: Basics is a new evidence-based treatment for children with autism spectrum disorders. It combines on-computer lessons, off-computer activities, data tracking, and communications tools. It is based on best-practices from Behavioral Research, Education, Speech and Language, and Developmental Psychology.
Contact: Tel: (800) 644-7811
Email:
info@teachtown.com
URL:
www.teachtown.com |
CG Therapeutics
CG Therapeutics is testing and commercializing a vaccine that elicits an
immune response to hCG for use as a contraceptive.
Contact:
Jonathan Green
Tel: (206)336-5605
Email: jongreen44@comcast.net
|
|
WRF is currently accepting applications to lease
WRF Venture Center offices.
Precedence is given to start-up companies commercializing new technology.
Please contact:
Morgan Hellar,
WRF Venture Center Manager, 206-336-5600, for rates and availability. |
|
